Wanbury Limited

Mumbai, India Founded: 1990 • Age: 36 yrs Listed
Anti-diabetic drugs and active pharmaceutical ingredients are manufactured.
Request Access
Report Incorrect Data
Page last updated

About Wanbury Limited

Wanbury Limited is a publicly listed company based in Mumbai (India) founded in 1990. Anti-diabetic drugs and active pharmaceutical ingredients are manufactured. The company has 1,380 employees. Its Indian entity Wanbury Limited reported revenue of ₹651 Cr. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Similar companies include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals; 1 of its 3 listed similar companies has raised funding.

Company details

Wanbury Limited was founded in 1990 and is headquartered in Mumbai, India. Operations are centered in the pharmaceutical sector, with a focus on producing active pharmaceutical ingredients for anti-diabetic treatments. Metformin is among the key products, which aids in insulin response and blood sugar regulation by limiting glucose absorption and liver production. The company maintains a notable position in the industry through its manufacturing processes.

  • Headquarters Mumbai, India
  • Employees 1,380
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website wanbury.com
  • Social LinkedIn
  • Legal Name Wanbury Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹670 Cr

    WANBURY · NSE

  • Share Price
    ₹191.02

    -0.30% today

  • Revenue
    ₹600 Cr

    FY 2024-25 · +4.1% YoY

  • EBITDA
    ₹76.31 Cr

    Margin 12.7%

  • Net Profit
    ₹33.36 Cr

    FY 2024-25 · +0.4% YoY

  • P/E (TTM)
    15.4x

    P/B 8.5x

  • ROE
    20.0%

    ROCE 21.0%

  • Debt / Equity
    3.38

    Interest cover 58.6x

  • Employee Count
    1,380

Board of directors of Wanbury Limited (Wanbury Limited)

Wanbury Limited is the primary company behind Wanbury Limited. The boards of the 2 registered companies of Wanbury Limited currently have 9 directors; the longest-serving is Chandran Krishnamoorthy, appointed in 2010. 25 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Chandran Krishnamoorthy
DIN 00005868
Whole-time director01 Sep 201016 yrs 2 moWanbury Limited
Vijaykumar Shivaji Ayare
DIN 06383445
Director31 Oct 201214 yrsWanbury Pharma Limited
Anupama Vaidya
DIN 02713517
Director17 Mar 20224 yrs 7 moWanbury Limited
Venkat Kumar Ketha
DIN 01241885
Director15 Dec 20223 yrs 10 moWanbury Pharma Limited
Sunil Vasudev Kotyankar
DIN 00435377
Director15 Dec 20223 yrs 10 moWanbury Pharma Limited
Mohan Kumar Rayana
DIN 07878975
Whole-time director21 Aug 20233 yrs 2 moWanbury Limited
Mridul Sumanlal Mehta
DIN 10177545
Director12 Aug 20242 yrs 2 moWanbury Limited
Manojkumar Khubchand Gursahani
DIN 01064558
Director08 Jan 20251 yr 9 moWanbury Limited
Pallavur Sankar Dass Vaidyanathan
DIN 06604217
Director08 Jan 20251 yr 9 moWanbury Limited

People of Wanbury Limited

12 people are tracked at Wanbury Limited (7 in leadership, 5 in team); the tracked headcount is 1,380.

NameRoleGroup
Sanjay Singh
OwnerLeadership
Pramod Badave
Sr Vice President Quality And RegulatoryLeadership
Dr. Ravi Sharma
Head Of Information TechnologyLeadership
Balaji Vasudevan
Sr. Vice President - Global API Sales & MarketingLeadership
Vinod Verma
CFOLeadership
Kedar Raje
Deputy General ManagerLeadership
Sagar Patil
Head ProcurementLeadership
Asfhan Nevrekar
Senior Leader ITTeam
Srinivasa Rao Magapu
Jr Executive In QcTeam
Ripan Roy
Institution Business ManagerTeam
Jackson George
Senior ManagerTeam
Jitendra G
AssociateTeam
Premium access

Complete people profiles for Wanbury Limited

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Wanbury Limited

Wanbury Limited is a publicly listed company on the NSE with ticker symbol WANBURY in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date29 Jan 2007
  • Listed onNSE: WANBURY
  • Listed entityWanbury Limited
  • Exchange sectorHealth technology
  • ISININE107F01022
  • Share price₹193.38 · 2026-10-14
  • Market capitalisation₹676 Cr
  • Price to earnings11.9
  • EPS (diluted, trailing year)₹16.27
  • Volume (last session)37,301

Financials of Wanbury Limited

Exchange-reported figures of Wanbury Limited, the listed company behind Wanbury Limited (NSE: WANBURY).

Financial Highlights

FY 2024-25 · Consolidated
Revenue
₹600 Cr
+4.1% YoY
EBITDA
₹76.31 Cr
+9.0% YoY
Profit After Tax
₹33.36 Cr
+0.4% YoY
Net Worth
₹59.27 Cr
+112.1% YoY
Total Assets
₹257 Cr
+60.7% YoY
Total Debt
₹179 Cr
+53.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Income statement
Revenue600576500511393367391
Revenue growth+4.1%+15.2%-2.3%+30.2%+6.8%-6.1%-
EBITDA76.3170.0022.5835.3218.0223.4315.55
EBITDA margin+12.7%+12.2%+4.5%+6.9%+4.6%+6.4%+4.0%
Profit before tax29.5456.34(10.28)81.14(12.40)64.66(24.97)
Net profit33.3633.23(6.79)5.76(12.24)(18.05)(24.49)
Net profit margin+5.6%+5.8%-1.4%+1.1%-3.1%-4.9%-6.3%
EPS (₹)9.3217.09(3.18)24.94(5.04)25.790.00
Balance sheet
Total assets25716076.0588.9149.7358.4061.07
Net worth59.2727.95(32.81)(23.42)(156)(143)(209)
Total debt17911694.93100192190260
Cash & bank12.835.903.9325.3111.7016.705.25
Net working capital36.42(24.27)(106)(92.40)(142)(130)(131)
Cash flow
Cash from operations26.103.9819.8040.5216.6844.1329.73
Cash from investing(51.17)(16.63)(8.84)0.598.0463.66(3.07)
Cash from financing25.7314.55(31.99)(28.58)(17.39)(108)(26.78)
ParticularsJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
Revenue163172133161131139146144
Revenue growth (YoY)+24.5%+23.4%-8.3%+11.6%-10.4%---
Other income0.351.840.841.630.9426.480.690.76
EBITDA24.4429.6313.9420.0110.9818.1721.1517.34
EBITDA margin+15.0%+17.2%+10.4%+12.4%+8.4%+13.0%+14.5%+12.0%
Depreciation3.643.373.323.323.293.283.323.24
Interest7.549.0410.1710.157.597.468.267.67
Profit before tax13.6119.061.298.171.0433.9110.267.19
Tax0.12(1.20)0.070.150.000.27(0.02)(0.18)
Net profit13.4920.261.228.021.0433.6410.287.37
EPS (₹)3.955.980.352.340.3110.083.132.25
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue650600578500511393367
Revenue growth+8.5%+3.8%+15.6%-2.3%+30.2%+6.8%-
EBITDA10376.4172.1022.5835.3318.0223.43
EBITDA margin+15.9%+12.8%+12.5%+4.5%+6.9%+4.6%+6.4%
Profit before tax59.8029.5430.79(10.28)81.15(12.40)64.66
Net profit69.6628.4729.92(10.08)5.44(13.81)(18.17)
Net profit margin+10.7%+4.8%+5.2%-2.0%+1.1%-3.5%-4.9%
EPS (₹)18.939.329.28(3.18)24.94(5.04)25.79
Balance sheet
Total assets39425716274.9487.8648.6557.36
Net worth14459.2727.95(7.25)2.19(131)(118)
Total debt22617911668.2773.60166164
Cash & bank7.6312.835.903.8925.2711.6616.66
Net working capital11536.29(22.22)(107)(93.46)(143)(131)
Cash flow
Cash from operations31.5326.204.7019.8040.5216.6844.13
Cash from investing(56.40)(51.17)(16.63)(8.84)0.598.0463.66
Cash from financing22.4225.6313.87(31.99)(28.58)(17.39)(108)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue166165162160163172133161
Revenue growth (YoY)+1.5%-4.3%+21.7%-0.7%+24.5%---
Other income0.360.210.180.200.351.840.841.63
Total expenses149138136134139142120141
EBITDA16.2326.2426.6925.7824.4429.6313.9420.01
EBITDA margin+9.8%+15.9%+16.4%+16.1%+15.0%+17.2%+10.4%+12.4%
Depreciation4.043.233.743.703.643.373.323.32
Interest7.978.067.267.127.549.0410.1710.15
Profit before tax4.5815.1615.8715.1613.6119.061.298.17
Tax1.34(6.54)0.11(0.02)0.12(1.20)0.070.15

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 04 Nov 2026
ParticularsJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
Revenue163172133161131139146144
Revenue growth (YoY)+24.5%+23.4%-8.3%+11.6%-10.4%---
Other income0.351.840.841.630.9426.480.690.76
EBITDA24.4429.6313.9420.0110.9818.1721.1517.34
EBITDA margin+15.0%+17.2%+10.4%+12.4%+8.4%+13.0%+14.5%+12.0%
Depreciation3.643.373.323.323.293.283.323.24
Interest7.549.0410.1710.157.597.468.267.67
Profit before tax13.6119.061.298.171.0433.9110.267.19
Tax0.12(1.20)0.070.150.000.27(0.02)(0.18)
Net profit13.4920.261.228.021.0433.6410.287.37
EPS (₹)3.955.980.352.340.3110.083.132.25
ParticularsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Revenue600576500511393367391
Revenue growth+4.1%+15.2%-2.3%+30.2%+6.8%-6.1%-
Other income3.4928.550.9177.882.4083.789.33
Total expenses523506477476374344376
Employee cost10486.9281.0074.8164.1567.4875.89
EBITDA76.3170.0022.5835.3218.0223.4315.55
EBITDA margin+12.7%+12.2%+4.5%+6.9%+4.6%+6.4%+4.0%
Depreciation13.3113.0312.3811.459.759.689.97
Interest36.9529.1821.3920.6123.0732.8739.88
Profit before tax29.5456.34(10.28)81.14(12.40)64.66(24.97)
Tax(0.98)0.380.11(0.35)0.200.21(0.14)
Net profit33.3633.23(6.79)5.76(12.24)(18.05)(24.49)
Net profit margin+5.6%+5.8%-1.4%+1.1%-3.1%-4.9%-6.3%
EPS (₹)9.3217.09(3.18)24.94(5.04)25.790.00
ParticularsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Equity & liabilities
Share capital32.7732.7532.7132.6725.0225.0023.72
Reserves & surplus20.50(10.80)(65.52)(56.09)(181)(168)(233)
Shareholders' funds (net worth)59.2727.95(32.81)(23.42)(156)(143)(209)
Minority interest0.000.000.000.000.000.000.00
Secured loans17511063.6466.52160163232
Unsecured loans3.686.5331.2933.7432.3027.1627.16
Total debt17911694.93100192190260
Total liabilities25716076.0588.9149.7358.4061.07
Assets
Gross block293248239227216203202
Net block201167167167167164172
Capital work in progress5.383.011.612.3511.0113.898.97
Investments0.150.030.010.010.010.010.02
Inventories37.6836.0221.9949.7324.8512.2619.33
Sundry debtors11489.4468.9862.8034.4750.7944.41
Cash & bank balances12.835.903.9325.3111.7016.705.25
Loans & advances28.6527.9226.9133.4026.5110.1625.43
Total current assets19315912217197.5389.9194.42
Total current liabilities157184227264239220225
Net working capital36.42(24.27)(106)(92.40)(142)(130)(131)
Total assets25716076.0588.9149.7358.4061.07
ParticularsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Opening cash3.401.4922.5310.002.662.742.87
Net cash from operating activities26.103.9819.8040.5216.6844.1329.73
Net cash from investing activities(51.17)(16.63)(8.84)0.598.0463.66(3.07)
Net cash from financing activities25.7314.55(31.99)(28.58)(17.39)(108)(26.78)
Net change in cash0.661.91(21.03)12.527.34(0.08)(0.13)
Closing cash12.835.903.9325.3111.7016.705.25
ParticularsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Growth
Sales growth+4.1%+15.2%-2.3%+30.2%+6.8%-6.1%-
EBITDA growth+9.0%+210.0%-36.1%+96.0%-23.1%+50.7%-
PBT growth-47.6%+9998.0%-+9998.0%-+9998.0%+22.9%
Net income growth+0.4%+589.4%-217.9%+147.1%+32.2%+26.3%-
Revenue CAGR (3Y)+5.5%+13.6%+10.8%+9.3%+1.9%-5.4%-2.6%
EBITDA CAGR (3Y)+29.3%+57.2%-1.2%+31.5%-+8.2%-21.7%
Profitability & leverage
Net income margin+5.1%+9.7%-2.1%+15.9%-3.2%+17.5%-6.3%
Return on capital employed+21.0%+33.5%0.0%+16.1%0.0%+8.0%0.0%
Return on net worth+20.0%+49.8%0.0%+306.0%0.0%+36.2%0.0%
Debt / equity3.380.000.000.000.000.000.00
Long-term debt / equity2.830.000.000.000.000.000.00
Interest cover58.6551.22209.7186.34278.96239.05714.70
Efficiency & per share
Fixed asset turnover2.222.362.152.311.871.811.95
Inventory turnover16.2719.8513.9313.7121.1523.2624.16
Debtors turnover5.917.277.5810.519.217.7210.60
EPS (₹)9.3217.09(3.18)24.94(5.04)25.790.00
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)16.266.70(10.07)(7.27)(62.46)(57.39)(88.23)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue166165162160163172133161
Revenue growth (YoY)+1.5%-4.3%+21.7%-0.7%+24.5%---
Other income0.360.210.180.200.351.840.841.63
Total expenses149138136134139142120141
EBITDA16.2326.2426.6925.7824.4429.6313.9420.01
EBITDA margin+9.8%+15.9%+16.4%+16.1%+15.0%+17.2%+10.4%+12.4%
Depreciation4.043.233.743.703.643.373.323.32
Interest7.978.067.267.127.549.0410.1710.15
Profit before tax4.5815.1615.8715.1613.6119.061.298.17
Tax1.34(6.54)0.11(0.02)0.12(1.20)0.070.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue650600578500511393367
Revenue growth+8.5%+3.8%+15.6%-2.3%+30.2%+6.8%-
Other income0.943.490.900.9177.882.4083.78
Total expenses547523506477476374344
Employee cost12010286.9281.0074.8164.1567.48
EBITDA10376.4172.1022.5835.3318.0223.43
EBITDA margin+15.9%+12.8%+12.5%+4.5%+6.9%+4.6%+6.4%
Depreciation14.3113.4113.0312.3811.459.759.68
Interest29.9836.9529.1821.3920.6123.0732.87
Profit before tax59.8029.5430.79(10.28)81.15(12.40)64.66
Tax(6.33)(0.98)0.380.11(0.35)0.200.21
Net profit69.6628.4729.92(10.08)5.44(13.81)(18.17)
Net profit margin+10.7%+4.8%+5.2%-2.0%+1.1%-3.5%-4.9%
EPS (₹)18.939.329.28(3.18)24.94(5.04)25.79
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital34.9432.7732.7532.7132.6725.0225.00
Reserves & surplus11020.50(10.80)(39.96)(30.48)(156)(143)
Shareholders' funds (net worth)14459.2727.95(7.25)2.19(131)(118)
Secured loans21717510963.6466.72160163
Unsecured loans8.913.686.534.636.885.640.50
Total debt22617911668.2773.60166164
Total liabilities39425716274.9487.8648.6557.36
Assets
Gross block335293248239227216203
Net block229201167167167167164
Capital work in progress25.425.383.011.612.3511.0113.89
Investments0.030.150.030.010.010.010.01
Inventories50.6337.6836.0221.9949.7324.8512.26
Sundry debtors14311488.7668.9862.8034.4750.79
Cash & bank balances7.6312.835.903.8925.2711.6616.66
Loans & advances37.0228.5227.9225.3331.8924.978.67
Total current assets23919315912017095.9588.38
Total current liabilities124157181227263239220
Net working capital11536.29(22.22)(107)(93.46)(143)(131)
Total assets39425716274.9487.8648.6557.36
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash4.063.401.4622.499.962.622.71
Net cash from operating activities31.5326.204.7019.8040.5216.6844.13
Net cash from investing activities(56.40)(51.17)(16.63)(8.84)0.598.0463.66
Net cash from financing activities22.4225.6313.87(31.99)(28.58)(17.39)(108)
Net change in cash(2.45)0.661.94(21.03)12.537.34(0.09)
Closing cash7.6312.835.903.8925.2711.6616.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.5%+3.8%+15.6%-2.3%+30.2%+6.8%-
EBITDA growth+35.0%+6.0%+219.3%-36.1%+96.1%-23.1%-
PBT growth+102.4%-4.1%+9998.0%-+9998.0%-+9998.0%
Net income growth+144.7%-4.9%+396.8%-285.3%+139.4%+24.0%-
Revenue CAGR (3Y)+9.2%+5.5%+13.8%+10.8%+9.3%+1.9%-5.6%
EBITDA CAGR (3Y)+65.9%+29.3%+58.8%-1.2%+31.5%-+7.5%
Profitability & leverage
Net income margin+10.2%+5.1%+5.3%-2.1%+15.9%-3.2%+17.5%
Return on capital employed+22.4%+20.0%+31.9%0.0%+17.5%0.0%+8.5%
Return on net worth+37.3%+18.3%+38.3%0.0%+37.0%0.0%+49.0%
Debt / equity1.993.388.940.000.000.000.00
Long-term debt / equity1.522.834.290.000.000.000.00
Interest cover33.7558.6549.40209.7186.31278.96239.05
Efficiency & per share
Fixed asset turnover2.072.212.372.152.311.871.81
Inventory turnover14.7316.2719.9213.9313.7121.1523.26
Debtors turnover5.055.917.337.5810.519.217.72
EPS (₹)18.939.329.28(3.18)24.94(5.04)25.79
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)41.3416.266.70(2.26)0.57(52.23)(47.14)

Similar companies to Wanbury Limited

Wanbury Limited has 3 listed similar companies in our database, 1 of them funded. They include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Indoco Remedies
indoco.com1947Mumbai, India6,291
APIs manufacturing and formulation services are provided in therapeutic segments.
Concord Biotech
concordbiotech.com2000Ahmedabad, India1,598
APIs and enzymes are manufactured through fermentation by the CDMO.
BDR Pharmaceuticals Internationals
bdrpharma.com2003Mumbai, India$88.16M1,864
APIs and finished products are developed and manufactured.
Premium access

Detailed similar companies of Wanbury Limited

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Wanbury Limited

The website of Wanbury Limited (wanbury.com) receives about 2.4K visits a month and ranks #9,325,375 among all websites worldwide, #7,649 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    2.4K

    ▲ 17.2% vs previous month

  • Global rank
    #9,325,375

    among all websites

  • Category rank
    #7,649

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Wanbury Limited. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
emcure.co.in
emcure.co.in
100%
–
Wintac
wintaclimited.com
53%
View details
UB Group
theubgroup.com
51%
2.6K#6,302,260View details
Konkan Industrial Publications
konkanindustrialpublications.com
39%
#855,631View details
itsmyascent.com
itsmyascent.com
37%
–

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Wanbury Limited (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Wanbury Limited

Wanbury: Gets Australian TGA GMP Compliance Certificate For Tanuku Plant, Enhancing Global Pharmaceutical Manufacturing Standards.
Exchange Update • 5 days ago
Wanbury: Company Gets 9 "No DMF Deficiency" Letters From USFDA For Metformin HCL, Expands Metformin Business In Saudi Arabia And Mexico.
Exchange Update • 19 days ago
Wanbury: Company Highlights Strong Regulatory Filings Quality, Creates New Business Opportunities In US Market
Exchange Update • 19 days ago
Wanbury: Introduces BerrySoft™ Baby Product Line In Several Indian States; Expands Into Pediatric Dermatology Field; Obtained GST Registration In 5 States And CF Drug Licenses In Various Areas.
Exchange Update • 23 days ago
Wanbury: Files New Drug Master File For Tramadol HCl In South Africa, Also Submitted DMF For Metformin HCl API In Philippines And Singapore, Added KSM Vendors For Supply Chain Stability
Exchange Update • 27 days ago
Wanbury June-Quarter PAT 32.4 Million Rupees
Reuters • 2 months ago
Wanbury Receives No DMF Deficiency Letter From USFDA For Multiple Andas
Reuters • 3 months ago
Wanbury Says Completion Of US FDA Inspection At Tanuku Facility
Reuters • 3 months ago
Wanbury Says USFDA Inspection At Tanuku Facility Conducted From July 13 To 17
Reuters • 3 months ago
Wanbury Approves Incorporation Of Subsidiary Company In India
Reuters • 4 months ago
Premium access

Complete news archive for Wanbury Limited

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Wanbury Limited

Wanbury Limited was founded in 1990.

Wanbury Limited is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Wanbury Limited has 1,380 employees.

The primary company behind Wanbury Limited, Wanbury Limited, reported revenue of ₹651 Cr for FY 2026, up 8% year on year.

Wanbury Limited was founded in 1990 and is headquartered in Mumbai, India. Operations are centered in the pharmaceutical sector, with a focus on producing active pharmaceutical ingredients for anti-diabetic treatments. Metformin is among the key products, which aids in insulin response and blood sugar regulation by limiting glucose absorption and liver production. The company maintains a notable position in the industry through its manufacturing processes.

Wanbury Limited's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Indoco Remedies.

Yes, Wanbury Limited is publicly traded on NSE under the ticker symbol WANBURY.

Wanbury Limited is associated with 2 legal entities: Wanbury Limited, Wanbury Pharma Limited.

The legal entities of Wanbury Limited currently have 11 directors, including Vijaykumar Shivaji Ayare, Venkat Kumar Ketha, Sunil Vasudev Kotyankar and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available